Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 379
Filtrar
1.
Front Endocrinol (Lausanne) ; 12: 609134, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34025574

RESUMEN

Background: Berberine is a plant alkaloid that has multiple beneficial effects against intestine inflammation. In our previous study, we have found that berberine also possesses an antidiabetic effect. However, whether berberine is useful in the prevention of type 2 diabetes mellitus (T2DM) through its effect on intestine endocrine function and gut microbiota is unclear. Aim: To investigate the effects of berberine in the prevention of T2DM, as well as its effects on intestine GLP-2 secretion and gut microbiota in ZDF rats. Methods: Twenty Zucker Diabetic Fatty (ZDF) rats were fed a high-energy diet until they exhibited impaired glucose tolerance (IGT). The rats were then divided into two groups to receive berberine (100 mg/kg/d; berberine group) or vehicle (IGT group) by gavage for 3 weeks. Five Zucker Lean (ZL) rats were used as controls. Fasting blood glucose (FBG) was measured, an oral glucose tolerance test was performed, and the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was calculated. Intestinal expression of TLR-4, NF-κB, TNF-α, mucin, zona occludens-1 (ZO-1) and occludin were assessed (immunohistochemistry). Plasma levels and glutamine-induced intestinal secretion of glucagon-like peptide-1 (GLP-1) and GLP-2 were measured (enzyme-linked immunosorbent assay). The plasma lipopolysaccharide (LPS) level was measured. Fecal DNA extraction, pyrosequencing, and bioinformatics analysis were performed. Results: After 3 weeks of intervention, diabetes developed in all rats in the IGT group, but only 30% of rats in the berberine group. Treatment with berberine was associated with reductions in food intake, FBG level, insulin resistance, and plasma LPS level, as well as increases in fasting plasma GLP-2 level and glutamine-induced intestinal GLP-2 secretion. Berberine could increase the goblet cell number and villi length, and also reverse the suppressed expressions of mucin, occludin, ZO-1 and the upregulated expressions of TLR-4, NF-κB and TNF-α induced in IGT rats (P<0.05). Berberine also improved the structure of the gut microbiota and restored species diversity. Conclusion: Berberine may slow the progression of prediabetes to T2DM in ZDF rats by improving GLP-2 secretion, intestinal permeability, and the structure of the gut microbiota.


Asunto(s)
Berberina/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Péptido 2 Similar al Glucagón/metabolismo , Mucosa Intestinal/efectos de los fármacos , Estado Prediabético , Animales , Berberina/uso terapéutico , Células Cultivadas , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/microbiología , Diabetes Mellitus Experimental/prevención & control , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/microbiología , Diabetes Mellitus Tipo 2/prevención & control , Progresión de la Enfermedad , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Mucosa Intestinal/patología , Secreciones Intestinales/efectos de los fármacos , Secreciones Intestinales/metabolismo , Masculino , Obesidad/complicaciones , Obesidad/metabolismo , Obesidad/microbiología , Obesidad/patología , Estado Prediabético/tratamiento farmacológico , Estado Prediabético/metabolismo , Estado Prediabético/microbiología , Estado Prediabético/patología , Ratas , Ratas Zucker
2.
Mol Pharm ; 16(10): 4121-4130, 2019 10 07.
Artículo en Inglés | MEDLINE | ID: mdl-31525051

RESUMEN

In this work, two different approaches have been developed to predict the food effect and the bioequivalence of marketed itraconazole (ITRA) formulations. Kinetic solubility and simultaneous dissolution-permeation tests of three (ITRA) formulations (Sporanox capsules and solution and SUBA-ITRA capsules) were carried out in simulated fasted and fed states. Fraction of dose absorbed ratios estimating food effect and bioequivalence were calculated based on these results and were compared to the in vivo study results published by Medicines Agencies. The comparison demonstrated that kinetic solubility and flux values could be used as input parameters for biopharmaceutics modeling and simulations to estimate food effect and bioequivalence. Both prediction methods were able to determine a slightly negative food effect in the case of the Sporanox solution and also a pronounced positive food effect for the Sporanox capsule. Superior bioavailability was predicted when the Sporanox solution was compared to the Sporanox capsule (in agreement with in vivo data).


Asunto(s)
Química Farmacéutica , Composición de Medicamentos , Tracto Gastrointestinal/efectos de los fármacos , Secreciones Intestinales/efectos de los fármacos , Itraconazol/farmacología , Antifúngicos/farmacología , Disponibilidad Biológica , Humanos , Modelos Teóricos , Solubilidad , Equivalencia Terapéutica
3.
J Pharmacol Sci ; 140(3): 273-283, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-31444000

RESUMEN

Secretory diarrhea is one of the most common causes of death world-wide especially in children under 5 years old. Isoliquiritigenin (ISLQ), a plant-derived chalcone, has previously been shown to exert anti-secretory action in vitro and in vivo by inhibiting CFTR Cl- channels. However, its CFTR inhibition potency is considerably low (IC50 > 10 µM) with unknown mechanism of action. This study aimed to identify novel chalcone derivatives with improved potency and explore their mechanism of action. Screening of 27 chalcone derivatives identified CHAL-025 as the most potent chalcone analog that reversibly inhibited CFTR-mediated Cl- secretion in T84 cells with an IC50 of ∼1.5 µM. As analyzed by electrophysiological and biochemical analyses, the mechanism of CFTR inhibition by CHAL-025 is through AMP-activated protein kinase (AMPK), a negative regulator of CFTR activity. Furthermore, Western blot analyses and molecular dynamics (MD) results suggest that CHAL-025 activates AMPK by binding at the allosteric site of an upstream kinase calcium/calmodulin-dependent protein kinase kinase ß (CaMKKß). Interestingly, CHAL-025 inhibited both cholera toxin (CT) and bile acid-induced Cl- secretion in T84 cells and prevented CT-induced intestinal fluid secretion in mice. Therefore, CHAL-025 represents a promising anti-diarrheal agent that inhibits CFTR Cl- channel activity via CaMKKß-AMPK pathways.


Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Chalconas/farmacología , Canales de Cloruro/antagonistas & inhibidores , Regulador de Conductancia de Transmembrana de Fibrosis Quística/antagonistas & inhibidores , Diarrea/tratamiento farmacológico , Animales , Transporte Biológico/efectos de los fármacos , Quinasa de la Proteína Quinasa Dependiente de Calcio-Calmodulina/metabolismo , Línea Celular , Cloruros/metabolismo , Diarrea/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Humanos , Secreciones Intestinales/efectos de los fármacos , Secreciones Intestinales/metabolismo , Masculino , Ratones , Ratones Endogámicos ICR
4.
J Ethnopharmacol ; 239: 111503, 2019 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-30217790

RESUMEN

ETHNOPHARMACOLOGICAL RELEVANCE: Origanum majorana L. (Lamiaceae) is commonly used in Moroccan folk medicine to treat infantile colic, abdominal discomfort and diarrhea. Liquid stools and abdominal discomfort observed in acute infectious diarrhea are the consequences of imbalance between intestinal water secretion and absorption in the lumen, and relaxation of smooth muscle surrounding the intestinal mucosa. AIM OF THE STUDY: The objective of our study was to see if aqueous extract of Origanum majorana L. (AEOM) may exhibit an effect on those deleterious mechanisms. MATERIALS AND METHODS: The effect of AEOM on electrogenic Cl- secretion and Na+ absorption, the two main mechanisms underlying water movement in the intestine, was assessed on intestinal pieces of mice intestine mounted, in vitro, in Ussing chambers. AEOM effect on muscle relaxation was measured on rat intestinal smooth muscle mounted in an isotonic transducer. RESULTS: 1) AEOM placed on the serosal (i.e. blood) side of the piece of jejunum entirely inhibited in a concentration-dependent manner the Forskolin-induced electrogenic chloride secretion, with an IC50 = 654 ±â€¯8 µg/mL. 2) AEOM placed on the mucosal (i.e. luminal) side stimulated in a concentration-dependent manner an electrogenic Na+ absorption, with an IC50 = 476.9 ±â€¯1 µg/mL. 3) AEOM (1 mg/mL) inhibition of Forskolin-induced electrogenic secretion was almost entirely prevented by prior exposure to Ca++ channels or neurotransmitters inhibitors. 4) AEOM (1 mg/mL) proabsorptive effect was greater in the ileum and progressively declined in the jejunum, distal colon and proximal colon (minimal). 5) AEOM inhibited in a concentration-dependent manner smooth muscle Carbachol or KCl induced contraction, with an IC50 = 1.64 ±â€¯0.2 mg/mL or 1.92 ±â€¯0.8 mg/mL, respectively. CONCLUSION: the present results indicate that aqueous extract of Origanum majorana L. exhibit positive cooperative effects on the main mechanisms that are involved in acute infectious diarrhea.


Asunto(s)
Diarrea , Mucosa Intestinal/efectos de los fármacos , Origanum , Extractos Vegetales/farmacología , Animales , Cloruros/metabolismo , Diarrea/tratamiento farmacológico , Diarrea/metabolismo , Diarrea/fisiopatología , Femenino , Absorción Intestinal/efectos de los fármacos , Mucosa Intestinal/fisiología , Secreciones Intestinales/efectos de los fármacos , Masculino , Medicinas Tradicionales Africanas , Ratones Endogámicos C57BL , Marruecos , Contracción Muscular/efectos de los fármacos , Fitoquímicos/aislamiento & purificación , Fitoquímicos/farmacología , Fitoquímicos/uso terapéutico , Componentes Aéreos de las Plantas , Extractos Vegetales/química , Extractos Vegetales/uso terapéutico , Ratas Wistar , Sodio/metabolismo
5.
Pflugers Arch ; 471(2): 313-327, 2019 02.
Artículo en Inglés | MEDLINE | ID: mdl-30250967

RESUMEN

Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are synthesized from dietary carbohydrates by colonic bacterial fermentation. These SCFAs supply energy, suppress cancer, and affect ion transport. However, their roles in ion transport and regulation in the intracellular environment remain unknown. In order to elucidate the roles of SCFAs, we measured short-circuit currents (ISC) and performed RT-PCR and immunohistochemical analyses of ion transporters in rat rectal colon. The application of 30 mM butyrate shifted ISC in a negative direction, but did not attenuate the activity of epithelial Na+ channels (ENaC). The application of bumetanide, a Na+-K+-2Cl- cotransporter inhibitor, to the basolateral side reduced the negative ISC shift induced by butyrate. The application of XE991, a KCNQ-type K+ channel inhibitor, to the apical side decreased the ISC shift induced by butyrate in a dose-dependent manner. The ISC shift was independent of HCO3- and insensitive to ibuprofen, an SMCT1 inhibitor. The mucosa from rat rectal colon expressed mRNAs of H+-coupled monocarboxylate transporters (MCT1, MCT4, and MCT5, also referred to as SLC16A1, SLC16A3, and SLC16A4, respectively). RT-PCR and immunofluorescence analyses demonstrated that KCNQ2 and KCNQ4 localized to the apical membrane of surface cells in rat rectal colon. These results indicate that butyrate, which may be transported by H+-coupled monocarboxylate transporters, activates K+ secretion through KCNQ-type K+ channels on the apical membrane in rat rectal colon. KCNQ-type K+ channels may play a role in intestinal secretion and defense mechanisms in the gastrointestinal tract.


Asunto(s)
Butiratos/metabolismo , Colon/metabolismo , Secreciones Intestinales/metabolismo , Potasio/metabolismo , Recto/metabolismo , Animales , Antracenos/farmacología , Bumetanida/farmacología , Cloruros/metabolismo , Colon/efectos de los fármacos , Ácidos Grasos Volátiles/metabolismo , Absorción Intestinal/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Secreciones Intestinales/efectos de los fármacos , Transporte Iónico/efectos de los fármacos , Transporte Iónico/fisiología , Canales de Potasio KCNQ/metabolismo , Masculino , Transportadores de Ácidos Monocarboxílicos/metabolismo , Propionatos/farmacología , Ratas , Ratas Sprague-Dawley , Sodio/metabolismo , Canales de Sodio/metabolismo
6.
An Acad Bras Cienc ; 91(1): e20170932, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30569966

RESUMEN

This study investigated the effects of the ethanolic extract from the bark of Combretum leprosum (ECL) on intestinal transit and castor-oil induced diarrhea in mice. The oral administration of ECL (750 and 1000 mg/kg) slowed intestinal transit (ID50 of 455 mg/kg). The ECL (250-1000 mg/kg) reduced castor-oil induced diarrhea, in a time- and dose-dependent manner (p < 0.05). To determine if antidiarrheal effect of ECL involves α2-adrenergic or opioid receptor activation, the mice were pretreated with antagonists of these receptors, yohimbine or naloxone respectively. None of these drugs inhibited the antidiarrheal effect of ECL. To test if antidiarrheal effect of ECL is due to an antisecretory action, we realized the enteropooling assay on rats. The ECL increased bowel content and did not inhibit intestinal fluid secretion increase induced by misoprostol (100 µg/kg, s.c.). To determine if antimotility effect of ECL is due to a reduction on gastric motility, we realized the organ bath assay in the rat fundus stomach. Isotonic recordings show that the carbachol /KCl - induced contraction was not reversed by the addition of ECL. In conclusion, our results suggest that ECL contains antidiarrheal compounds and these compounds could induce a reduction of intestinal tract motility.


Asunto(s)
Antidiarreicos/uso terapéutico , Combretum/química , Diarrea/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Animales , Antidiarreicos/farmacología , Aceite de Ricino , Diarrea/etiología , Femenino , Tránsito Gastrointestinal/efectos de los fármacos , Secreciones Intestinales/efectos de los fármacos , Ratones , Extractos Vegetales/farmacología , Distribución Aleatoria , Ratas Wistar , Receptores Adrenérgicos alfa/efectos de los fármacos , Receptores Opioides/efectos de los fármacos , Reproducibilidad de los Resultados , Factores de Tiempo , Resultado del Tratamiento
7.
JPEN J Parenter Enteral Nutr ; 42(8): 1342-1348, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-29603286

RESUMEN

BACKGROUND: Plant foods may stimulate intestinal secretion through chemicals designed to deter herbivores, including lactucins in lettuce and rhein in rhubarb. This may increase ileostomy output and induce diarrhoea in people with intact bowels. OBJECTIVE: We aimed to determine the effect of food on intestinal water content using Magnetic Resonance Imaging (MRI). DESIGN: A three period crossover trial of isocaloric meals in adults without bowel disorders. Meals: 2 slices white bread with 10 g butter; 300 g rhubarb with 60 mL lactose free cream; 300 g lettuce with 30 mL mayonnaise. PRIMARY OUTCOME: Area under curve (AUC) small bowel water content (SBWC) using MRI. SECONDARY OUTCOMES: ascending colon water content; T1 relaxation time of ascending colon (T1AC); gastric volume; visual analogue scales of bloating and satiety (0-100). MRI analysts were blinded. Scanned fasting and hourly to 180 min postprandial. Symptoms scored half-hourly. RESULTS: 9 female and 6 male subjects completed the study. AUC SBWC fell after bread but rose after lettuce and even more after rhubarb, difference from baseline being (Bread AUC -5662 (1209) ml.min vs Lettuce 3194 (1574) ml.min and Rhubarb 10586 (1629) ml.min (P < 0.01). Rhubarb induced a rise in T1AC but differences at 3 hours were not significant (P = 0.06). Gastric volume at T = 0 significantly was higher for both lettuce and rhubarb (571 ± 92 and 558 ± 89 mls) respectively compared to bread (314 ± 108 mls) (p < 0.0001). Symptom scores were higher for lettuce > rhubarb > bread. CONCLUSION: Lettuce and rhubarb meals increased intestinal water content, demonstrating how different foods can alter ileal flow and stool consistency.


Asunto(s)
Contenido Digestivo/química , Secreciones Intestinales/efectos de los fármacos , Intestino Delgado/efectos de los fármacos , Lactuca/química , Rheum/química , Triticum , Agua/análisis , Antraquinonas/farmacología , Pan , Colon/efectos de los fármacos , Colon/fisiología , Estudios Cruzados , Heces/química , Femenino , Tránsito Gastrointestinal , Humanos , Intestino Delgado/fisiología , Lactonas/farmacología , Imagen por Resonancia Magnética/métodos , Masculino , Comidas , Forboles/farmacología , Extractos Vegetales/farmacología , Periodo Posprandial , Valores de Referencia , Sesquiterpenos/farmacología , Estómago , Adulto Joven
8.
Arch Physiol Biochem ; 124(5): 430-435, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-29277113

RESUMEN

CONTEXT: Sweet taste receptors (STRs) involve in regulating the release of glucose-stimulated glucagon-like peptide-1 (GLP-1). Our in vivo and in vitro studies found that 3-deoxyglucosone (3DG) inhibited glucose-stimulated GLP-1 secretion. OBJECTIVE: This study investigated the role of STRs in 3DG-induced inhibition of high glucose-stimulated GLP-1 secretion. METHODS: STC-1 cells were incubated with lactisole or 3DG for 1 h under 25 mM glucose conditions. Western blotting was used to study the expression of STRs signaling molecules and ELISA was used to analyse GLP-1 and cyclic adenosine monophosphate (cAMP) levels. RESULTS: Lactisole inhibited GLP-1 secretion. Exposure to 25 mM glucose increased the expressions of STRs subunits when compared with 5.6 mM glucose. 3DG decreased GLP-1 secretion and STRs subunits expressions, with affecting other components of STRs pathway, including the downregulation of transient receptor potential cation channel subfamily M member 5 (TRPM5) expression and the reduction of intracellular cAMP levels. CONCLUSION: 3DG attenuates high glucose-stimulated GLP-1 secretion by reducing STR subunit expression and downstream signaling components.


Asunto(s)
Desoxiglucosa/análogos & derivados , Regulación hacia Abajo , Células Enteroendocrinas/metabolismo , Péptido 1 Similar al Glucagón/metabolismo , Glucosa/metabolismo , Receptores Acoplados a Proteínas G/antagonistas & inhibidores , Sistemas de Mensajero Secundario , Animales , Derivados del Benceno/farmacología , Western Blotting , Línea Celular , AMP Cíclico/metabolismo , Desoxiglucosa/metabolismo , Azúcares de la Dieta/metabolismo , Regulación hacia Abajo/efectos de los fármacos , Células Enteroendocrinas/efectos de los fármacos , Ensayo de Inmunoadsorción Enzimática , Péptido 1 Similar al Glucagón/agonistas , Péptido 1 Similar al Glucagón/antagonistas & inhibidores , Secreciones Intestinales/efectos de los fármacos , Secreciones Intestinales/metabolismo , Ratones , Concentración Osmolar , Subunidades de Proteína/agonistas , Subunidades de Proteína/antagonistas & inhibidores , Subunidades de Proteína/metabolismo , Receptores Acoplados a Proteínas G/agonistas , Receptores Acoplados a Proteínas G/metabolismo , Sistemas de Mensajero Secundario/efectos de los fármacos , Canales Catiónicos TRPM/agonistas , Canales Catiónicos TRPM/antagonistas & inhibidores , Canales Catiónicos TRPM/metabolismo
9.
World J Gastroenterol ; 23(42): 7563-7571, 2017 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-29204056

RESUMEN

AIM: To investigate the effect of Hemp seed soft capsule (HSCC) on colonic ion transport and its related mechanisms in constipation rats. METHODS: Sprague-Dawley male rats were randomly divided into three groups: normal group, constipation group and HSSC group. Rats in the constipation and HSSC groups were administrated loperamide 3 mg/kg per day orally for 12 d to induce the constipation model. Then, the HSSC group was given HSSC 0.126 g/kg per day by gavage for 7 d. The normal and constipation groups were treated with distilled water. After the treatment, the fecal wet weight and water content were measured. The basal short-circuit current (Isc) and resistance were measured by an Ussing Chamber. Besides the in vivo drug delivery experiment above, an in vitro drug application experiment was also conducted. The accumulative concentrations of HSSC (0.1 mg/mL, 0.5 mg/mL, 1.0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 10.0 mg/mL and 25.0 mg/mL) were added to the normal isolated colonic mucosa and the Isc was recorded. Further, after the application of either ion (Cl- or HCO3-) substitution, ion channel-related inhibitor (N-phenylanthranilic acid, glybenclamide, 4,4-diisothiocyano-2,2-stilbenedisulfonic acid or bumetanide) or neural pathway inhibitor [tetrodotoxin (TTX), atropine, or hexamethonium], the Isc induced by HSSC was also measured. RESULTS: In the constipation group, the fecal wet weight and the water content were decreased in comparison with the normal group (P < 0.01). After the treatment with HSSC, the fecal wet weight and the water content in the HSSC group were increased, compared with the constipation group (P < 0.01). In the constipation group, the basal Isc was decreased and resistance was increased, in comparison with the normal group (P < 0.01). After the treatment with HSSC, the basal Isc was increased (P < 0.05) and resistance was decreased (P < 0.01) in the HSSC group compared with the constipation group. In the in vitro experiment, beginning with the concentration of 1.0 mg/mL, differences in Isc were found between the experimental mucosa (with HSSC added) and control mucosa. The Isc of experimental mucosa was higher than that of control mucosa under the same concentration (1.0 mg/mL, P < 0.05; 2.5-25 mg/mL, P < 0.01). After the Cl- or HCO3- removal and pretreated with different inhibitors (cAMP-dependent and Ca2+-dependent Cl- channels, Na+-K+-2Cl- cotransporter (NKCC), Na+-HCO3- cotransporter or Cl-/HCO3- exchanger inhibitor), there were differences between experimental mucosa and control mucosa; the Isc of experimental mucosa was lower than that of control mucosa under the same concentration (P < 0.05). Meanwhile, after pretreatment with neural pathway inhibitor (TTX, atropine, or hexamethonium), there were no differences between experimental mucosa and control mucosa under the same concentration (P > 0.05). CONCLUSION: HSSC ameliorates constipation by increasing colonic secretion, which is mediated via the coaction of cAMP-dependent and Ca2+-dependent Cl- channels, NKCC, Na+-HCO3- cotransporter or Cl-/HCO3- exchanger.


Asunto(s)
Cannabis , Estreñimiento/tratamiento farmacológico , Secreciones Intestinales/efectos de los fármacos , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Animales , Bicarbonatos , Bumetanida , Cloruros , Colon/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Mucosa Intestinal/efectos de los fármacos , Masculino , Vías Nerviosas , Preparaciones de Plantas/farmacología , Distribución Aleatoria , Ratas Sprague-Dawley , ortoaminobenzoatos
10.
World J Gastroenterol ; 23(24): 4381-4389, 2017 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-28706420

RESUMEN

AIM: To investigate the acute toxicity, phytochemical profile, antidiarrheal activity and mechanisms of action of Maytenus erythroxylon (M. erythroxylon) ethanol extract. METHODS: A castor oil-induced diarrhea model was used to evaluate antidiarrheal activity. Intestinal transit and gastric emptying protocols were used to evaluate a possible antimotility effect. KATP channels, nitric oxide, presynaptic α2-adrenergic and tissue adrenergic receptors were investigated to uncover antimotility mechanisms of action and castor oil-induced enteropooling to elucidate antisecretory mechanisms. RESULTS: All tested doses of the extract (62.5, 125, 250 and 500 mg/kg) possessed antidiarrheal activity, with a significant decrease of the evacuation index. This activity is possibly related to a reduced gastric emptying (125, 250 and 500 mg/kg) and to a decreased percentage of intestinal transit for all tested doses. That last effect seems to be modulated by nitric oxide, KATP channels and tissue adrenergic receptors. Besides, the extract also presented antisecretory effect due to a decrease of intestinal fluid accumulation. CONCLUSION: The antidiarrheal effect of M. erythroxylon found in this study involves antimotility and antisecretory mechanisms that may be attributed to the chemical compounds found in this species: saponins, flavonoids, tannins, triterpenes and steroids.


Asunto(s)
Antidiarreicos/farmacología , Diarrea/tratamiento farmacológico , Vaciamiento Gástrico/efectos de los fármacos , Tránsito Gastrointestinal/efectos de los fármacos , Maytenus/química , Extractos Vegetales/farmacología , Animales , Antidiarreicos/uso terapéutico , Aceite de Ricino/toxicidad , Diarrea/inducido químicamente , Modelos Animales de Enfermedad , Etanol/química , Femenino , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Secreciones Intestinales/efectos de los fármacos , Canales KATP/metabolismo , Masculino , Ratones , Óxido Nítrico/metabolismo , Extractos Vegetales/uso terapéutico , Receptores Adrenérgicos/metabolismo
11.
BMC Vet Res ; 13(1): 181, 2017 Jun 17.
Artículo en Inglés | MEDLINE | ID: mdl-28623924

RESUMEN

BACKGROUND: Diarrhea in piglets is one of the main causes of animal death after weaning; zinc oxide (ZnO) has been used in high doses for the control of this sickness. The aim of this study was to determine the physicochemical properties of ZnO nanoparticles synthesized and immobilized on a chitosan/alginate (CH/SA) complex and investigate the antimicrobial activity and in vitro release profile of zinc (Zn2+) from these new compounds. The ZnO nanoparticles composites were prepared and combined with CH/SA or CH/SA and sodium tripolyphosphate (TPP). The structure and morphology of the composites were analyzed by characterization methods such as X-ray diffraction, FTIR spectroscopy, thermogravimetric analysis, atomic absorption spectrophotometry and scanning electron microscopy. RESULTS: The crystallite size of ZnO nano was 17 nm and the novel ZnO composites were effective in protecting ZnO in simulated gastric fluid, where Zn2+ reached a concentration six-fold higher than the levels obtained with the unprotected commercial-zinc oxide. In addition, the novel composites suggest effective antimicrobial activity against Escherichia coli and Staphylococcus aureus. CONCLUSIONS: The results described herein suggest that the novel nano composites may work as an alternative product for pig feeding as verified by the in vitro assays, and may also contribute to lower the zinc released in the environment by fecal excretion in animals waste.


Asunto(s)
Antibacterianos/farmacología , Jugo Gástrico/efectos de los fármacos , Nanopartículas , Óxido de Zinc/farmacología , Alginatos/química , Animales , Antibacterianos/administración & dosificación , Líquidos Corporales/efectos de los fármacos , Quitosano/química , Escherichia coli/efectos de los fármacos , Ácido Glucurónico/química , Ácidos Hexurónicos/química , Secreciones Intestinales/efectos de los fármacos , Pruebas de Sensibilidad Microbiana , Nanopartículas/química , Espectroscopía Infrarroja por Transformada de Fourier , Staphylococcus aureus/efectos de los fármacos , Porcinos , Difracción de Rayos X , Óxido de Zinc/administración & dosificación
12.
J Pharmacol Sci ; 134(2): 93-100, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28651800

RESUMEN

Intestinal Cl- secretion is involved in the pathogenesis of secretory diarrheas including cholera. We recently demonstrated that flufenamic acid (FFA) suppressed Vibrio cholerae El Tor variant-induced intestinal fluid secretion via mechanisms involving AMPK activation and NF-κB-suppression. The present study aimed to investigate the effect of FFA on transepithelial Cl- secretion in human intestinal epithelial (T84) cells. FFA inhibited cAMP-dependent Cl- secretion in T84 cell monolayers with IC50 of ∼8 µM. Other fenamate drugs including tolfenamic acid, meclofenamic acid and mefenamic acid exhibited the same effect albeit with lower potency. FFA also inhibited activities of CFTR, a cAMP-activated apical Cl- channel, and KCNQ1/KCNE3, a cAMP-activated basolateral K+ channel. Mechanisms of CFTR inhibition by FFA did not involve activation of its negative regulators. Interestingly, FFA inhibited Ca2+-dependent Cl- secretion with IC50 of ∼10 µM. FFA inhibited activities of Ca2+-activated Cl- channels and KCa3.1, a Ca2+-activated basolateral K+ channels, but had no effect on activities of Na+-K+-Cl- cotransporters and Na+-K+ ATPases. These results indicate that FFA inhibits both cAMP and Ca2+-dependent Cl- secretion by suppressing activities of both apical Cl- channels and basolateral K+ channels. FFA and other fenamate drugs may be useful in the treatment of secretory diarrheas.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Canales de Cloruro/antagonistas & inhibidores , Cloruros/metabolismo , Células Epiteliales/efectos de los fármacos , Ácido Flufenámico/farmacología , Intestinos/efectos de los fármacos , Proteínas Quinasas Activadas por AMP/metabolismo , Adenosina Trifosfatasas/metabolismo , Transporte Biológico , Línea Celular Tumoral , Canales de Cloruro/metabolismo , Células Epiteliales/metabolismo , Humanos , Mucosa Intestinal/metabolismo , Secreciones Intestinales/efectos de los fármacos , FN-kappa B/metabolismo , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio Calcio-Activados/metabolismo , Sodio/metabolismo
13.
Am J Physiol Cell Physiol ; 310(11): C1010-23, 2016 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-27076617

RESUMEN

Bile acids (BAs) play a complex role in colonic fluid secretion. We showed that dihydroxy BAs, but not the monohydroxy BA lithocholic acid (LCA), stimulate Cl(-) secretion in human colonic T84 cells (Ao M, Sarathy J, Domingue J, Alrefai WA, Rao MC. Am J Physiol Cell Physiol 305: C447-C456, 2013). In this study, we explored the effect of LCA on the action of other secretagogues in T84 cells. While LCA (50 µM, 15 min) drastically (>90%) inhibited FSK-stimulated short-circuit current (Isc), it did not alter carbachol-stimulated Isc LCA did not alter basal Isc, transepithelial resistance, cell viability, or cytotoxicity. LCA's inhibitory effect was dose dependent, acted faster from the apical membrane, rapid, and not immediately reversible. LCA also prevented the Isc stimulated by the cAMP-dependent secretagogues 8-bromo-cAMP, lubiprostone, or chenodeoxycholic acid (CDCA). The LCA inhibitory effect was BA specific, since CDCA, cholic acid, or taurodeoxycholic acid did not alter FSK or carbachol action. While LCA alone had no effect on intracellular cAMP concentration ([cAMP]i), it decreased FSK-stimulated [cAMP]i by 90%. Although LCA caused a small increase in intracellular Ca(2+) concentration ([Ca(2+)]i), chelation by BAPTA-AM did not reverse LCA's effect on Isc LCA action does not appear to involve known BA receptors, farnesoid X receptor, vitamin D receptor, muscarinic acetylcholine receptor M3, or bile acid-specific transmembrane G protein-coupled receptor 5. LCA significantly increased ERK1/2 phosphorylation, which was completely abolished by the MEK inhibitor PD-98059. Surprisingly PD-98059 did not reverse LCA's effect on Isc Finally, although LCA had no effect on basal Isc, nystatin permeabilization studies showed that LCA both stimulates an apical cystic fibrosis transmembrane conductance regulator Cl(-) current and inhibits a basolateral K(+) current. In summary, 50 µM LCA greatly inhibits cAMP-stimulated Cl(-) secretion, making low doses of LCA of potential therapeutic interest for diarrheal diseases.


Asunto(s)
Antidiarreicos/farmacología , Cloruros/metabolismo , Colon/efectos de los fármacos , AMP Cíclico/metabolismo , Regulador de Conductancia de Transmembrana de Fibrosis Quística/agonistas , Células Epiteliales/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Secreciones Intestinales/efectos de los fármacos , Ácido Litocólico/farmacología , Línea Celular , Colon/metabolismo , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Relación Dosis-Respuesta a Droga , Células Epiteliales/metabolismo , Humanos , Mucosa Intestinal/metabolismo , Secreciones Intestinales/metabolismo , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Fosforilación , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio/efectos de los fármacos , Canales de Potasio/metabolismo , Transducción de Señal/efectos de los fármacos , Factores de Tiempo
14.
J Pharmacol Sci ; 127(1): 150-3, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25704031

RESUMEN

Regulation of intestinal secretion is important for body fluid homeostasis. We investigated the role of three MAP kinases (MAPKs) as negative regulators in muscarinic cholinoceptor (mAChR)-mediated intestinal secretion in mice. Electrophysiological analyses revealed that mAChR stimulation enhanced intestinal chloride secretion, which was further augmented by the inhibition of JNK but not by that of ERK or p38 with specific inhibitors SP600125, U0126 or SB203580, respectively. Immunoblot analyses in colonic mucosa showed that mAChR stimulation increased MAPKs phosphorylation that was suppressed by the specific inhibitor for each MAPK. This suggests that JNK is a major negative regulator in mAChR-induced intestinal secretion.


Asunto(s)
Quinasas MAP Reguladas por Señal Extracelular/antagonistas & inhibidores , Secreciones Intestinales/efectos de los fármacos , Proteínas Quinasas JNK Activadas por Mitógenos/antagonistas & inhibidores , Agonistas Muscarínicos/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/antagonistas & inhibidores , Animales , Antracenos/farmacología , Butadienos/farmacología , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Imidazoles/farmacología , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Masculino , Potenciales de la Membrana/efectos de los fármacos , Ratones , Nitrilos/farmacología , Fosforilación/efectos de los fármacos , Piridinas/farmacología , Proteínas Quinasas p38 Activadas por Mitógenos/metabolismo
15.
Am J Physiol Regul Integr Comp Physiol ; 308(5): R400-10, 2015 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-25540100

RESUMEN

Guanylin (GN) action on seawater eel intestine was examined under simulated in vivo conditions, where isotonic luminal fluid has low NaCl and high MgSO4 (MgSO4 Ringer). In Ussing chamber, MgSO4 Ringer induced serosa-negative potential difference (PD) even after bumetanide treatment, which is due to the higher paracellular Na(+) permeability over Cl(-), as confirmed by the replacement by MgCl2 (no Cl(-) gradient) or Na2SO4 Ringer (no Na(+) gradient). Luminal GN reversed serosa-negative PD, probably by enhancing Cl(-) secretion into the lumen, as the GN effect was blocked by apical Cl(-) channel blockers [diphenylamine-2-carboxylic acid (DPC), 5-nitro-2-(3-phenylpropylamino) benzoic acid, glibenclamide but not cystic fibrosis transmembrane regulator (CFTR)inh-172] or replacement of luminal fluid by MgCl2 Ringer. The blockers' effect was undetectable when normal Ringer was on both sides. In the sac preparation, NaCl secretion occurred into the lumen (Na(+) > Cl(-)), and GN further enhanced Cl(-) secretion (Cl(-) > Na(+)), resulting in water secretion. These GN effects were also blocked by DPC. Quantitative analyses showed that isotonic NaCl is absorbed when luminal fluid is normal Ringer, but, when luminal fluid is MgSO4 Ringer, hypertonic NaCl, almost equivalent to seawater, is secreted into the lumen after GN. These results indicate that GN stimulates the secretion of hypertonic NaCl into the lumen of seawater eel intestine, like rectal gland of marine elasmobranchs, to get rid of excess NaCl although marine teleost intestine is thought to have only absorptive-type cells with a unique Na-K-Cl cotransport system. The secreted NaCl may activate the cotransport system and further help absorb water in the final segment of seawater eel intestine.


Asunto(s)
Canales de Cloruro/efectos de los fármacos , Cloruros/metabolismo , Anguilas/metabolismo , Hormonas Gastrointestinales/farmacología , Mucosa Intestinal/efectos de los fármacos , Secreciones Intestinales/efectos de los fármacos , Péptidos Natriuréticos/farmacología , Animales , Canales de Cloruro/metabolismo , Humanos , Absorción Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Secreciones Intestinales/metabolismo , Soluciones Isotónicas/metabolismo , Potenciales de la Membrana , Moduladores del Transporte de Membrana/farmacología , Solución de Ringer , Solución Salina Hipertónica/metabolismo , Agua de Mar , Factores de Tiempo , Agua/metabolismo
16.
J Physiol Sci ; 64(2): 119-28, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24421180

RESUMEN

Proteases play a diverse role in health and disease. An excessive concentration of proteases has been found in the feces of patients with inflammatory bowel disease or irritable bowel syndrome and been implicated in the pathogenesis of such disorders. This study examined the effect of the serine protease, trypsin, on intestinal epithelial anion secretion when added to the luminal side. A mucosal-submucosal sheet of the mouse cecum was mounted in Ussing chambers, and the short-circuit current (I sc) was measured. Trypsin added to the mucosal (luminal) side increased I sc with an ED50 value of approximately 10 µM. This I sc increase was suppressed by removing Cl(-) from the bathing solution. The I sc increase induced by 10-100 µM trypsin was substantially suppressed by tetrodotoxin, and partially inhibited by a neurokinin-1 receptor antagonist, but not by a muscarinic or nicotinic ACh-receptor antagonist. The trypsin-induced I sc increase was also significantly inhibited by a 5-hydroxytryptamine-3 receptor (5-HT3) antagonist and substantially suppressed by the simultaneous addition of both 5-HT3 and 5-HT4 receptor antagonists. We conclude that luminal trypsin activates the enteric reflex to induce anion secretion, 5-HT and substance P playing important mediating roles in this secreto-motor reflex. Luminal proteases may contribute to the cause of diarrhea occurring with some intestinal disorders.


Asunto(s)
Ciego/inervación , Cloruros/metabolismo , Sistema Nervioso Entérico/efectos de los fármacos , Mucosa Intestinal/inervación , Secreciones Intestinales/efectos de los fármacos , Tripsina/farmacología , Animales , Ciego/metabolismo , Conductividad Eléctrica , Sistema Nervioso Entérico/fisiología , Mucosa Intestinal/metabolismo , Secreciones Intestinales/metabolismo , Masculino , Ratones , Neurotransmisores/farmacología , Receptores Proteinasa-Activados/efectos de los fármacos , Receptores Proteinasa-Activados/metabolismo , Reflejo/efectos de los fármacos , Serotonina/metabolismo , Sustancia P/metabolismo , Factores de Tiempo
17.
Pancreas ; 42(2): 187-92, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23407480

RESUMEN

OBJECTIVES: The aim of this study was to establish a minimally invasive and simple screening test for detection of pancreatic ductal adenocarcinoma (PDAC) using duodenal juice (DJ). METHODS: Duodenal juice was collected prospectively before endoscopic retrograde cholangiopancreatography in 46 patients. A protease inhibitor was not added to the samples collected during the initial 2.5 minutes but was added in the latter 2.5 minutes. Thereafter, secretin was administered intravenously, and DJ was subsequently collected for additional 10 minutes. The sensitivities of carcinoembryonic antigen (CEA), S100 calcium-binding protein P (S100P), and interleukin 8 in DJ and pancreatic juice were assessed. RESULTS: There were 30 patients with PDAC and 16 with benign lesions. It was possible to collect an adequate amount of DJ without secretin administration. In the PDAC group, CEA concentrations in DJ were significantly higher than those in the benign group, even without the use of a protease inhibitor. S100P levels in DJ in the PDAC group were significantly higher than those in the benign group in the presence of the protease inhibitor. CONCLUSIONS: Duodenal juice collection during routine upper endoscopy and assessments of CEA and S100P in DJ might become a useful screening test for detection of PDAC.


Asunto(s)
Biomarcadores de Tumor/metabolismo , Proteínas de Unión al Calcio/metabolismo , Antígeno Carcinoembrionario/metabolismo , Carcinoma Ductal Pancreático/metabolismo , Duodeno/metabolismo , Secreciones Intestinales/metabolismo , Proteínas de Neoplasias/metabolismo , Neoplasias Pancreáticas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Ductal Pancreático/patología , Colangiopancreatografia Retrógrada Endoscópica , Duodeno/efectos de los fármacos , Femenino , Humanos , Interleucina-8/metabolismo , Secreciones Intestinales/efectos de los fármacos , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/patología , Valor Predictivo de las Pruebas , Pronóstico , Estudios Prospectivos , Inhibidores de Proteasas/administración & dosificación , Curva ROC , Secretina/administración & dosificación , Factores de Tiempo
18.
Curr Med Res Opin ; 29(2): 149-60, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23198977

RESUMEN

OBJECTIVES: The aims were: firstly, to review the definition and diagnosis of irritable bowel syndrome with constipation (IBS-C, a subtype of IBS); secondly, to critically assess current therapies for IBS-C with a focus on effectiveness for abdominal pain; and thirdly, to review clinical studies evaluating the efficacy of linaclotide, a therapy recently approved by the US Food and Drug Administration for the treatment of adults with IBS-C and chronic idiopathic constipation and the European Medicines Agency for the symptomatic treatment of moderate to severe IBS-C in adults, and in development for treatment of IBS-C worldwide. METHODS: A comprehensive literature review was performed to summarize IBS-C and current treatments. MEDLINE and gastrointestinal society congress proceedings were searched to identify data from linaclotide clinical studies in adults with IBS-C published between January 2010 and August 2012. RESULTS: IBS-C patients have chronic, relapsing symptoms. Rome III diagnostic criteria define the presence of chronic abdominal pain that improves with defecation and has onset associated with changes in stool frequency or form as a key element of IBS-C and other IBS subtypes. IBS-C patients generally are not completely satisfied with existing therapies. A therapy that treats bowel and abdominal symptoms effectively and can be taken safely on a chronic basis is a current unmet need for IBS-C patients. The guanylate cyclase-C agonist linaclotide has been shown to reduce visceral hypersensitivity in preclinical studies and to improve abdominal pain and constipation symptoms in phase 2 and 3 clinical trials of IBS-C patients. CONCLUSIONS: IBS-C is a functional gastrointestinal disorder with chronic, relapsing abdominal and constipation symptoms. By virtue of its effects in relieving abdominal pain by reducing visceral hypersensitivity and improving constipation symptoms by increasing intestinal secretion and accelerating transit, linaclotide may be uniquely positioned for a role in the management of IBS-C patients.


Asunto(s)
Estreñimiento/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Síndrome del Colon Irritable/tratamiento farmacológico , Péptidos/uso terapéutico , Dolor Abdominal/tratamiento farmacológico , Estreñimiento/diagnóstico , Estreñimiento/etiología , Femenino , Humanos , Secreciones Intestinales/efectos de los fármacos , Síndrome del Colon Irritable/complicaciones , Síndrome del Colon Irritable/diagnóstico , Masculino , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
19.
Cell Physiol Biochem ; 30(1): 137-50, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22759962

RESUMEN

BACKGROUND/AIMS: Daily subcutaneous injections with the phytoestrogen genistein, 600 mg/ kg genistein/day (600G) significantly increased intestinal chloride (Cl(-)) secretion (I(sc), µA/cm(2)) in C57BL/6J female and male murine jejunum after 1-2-weeks treatment. METHODS AND RESULTS: In 600G females, basolateral application of the adenylate cyclase inhibitor MDL-12330A (10 µM) significantly reduced basal and total I(sc) in the presence of forskolin (27 and 40% respectively, P < 0.05), with no effect in 600G males, suggesting that 600G-mediated increases in I(sc) in females are due to an adenylate cyclase-dependent mechanism. Concomitant injections with the non-selective estrogen receptor (ER) antagonist ICI-182780 (25 mg/kg/day) resulted in a significant inhibition of basal I(sc) in males (38%, P < 0.05), but was without effect in females (further reinforcing an ER-independent mechanism of action). The ERα-selective antagonist (MPP, 25 mg/kg/day) similarly significantly inhibited the basal I(sc) (37%, P < 0.05) in males, whereas the ERß-selective antagonist (PHTPP, 25 mg/kg/day) was without effect, suggesting that 600G-mediated increases in I (sc) in male mice are due to an ERα-dependent mechanism. Jejunum ERα/actin expression was significantly increased by 600G in males. Compared to intact mice, orchiectomy has differing effects on 600G-mediated basal Isc; castration (CAST) abolished the 600G-mediated increases in I(sc), and ovariectomy (OVX) had no effect on the 600G-stimulated increases in I(sc). Daily estradiol injections (10-20 mg/kg body weight estradiol (10E2 or 20E2) had no effect in intact females, whereas 10E2 significantly increased basal I(sc) in OVX females. CONCLUSION: These data suggest that daily estradiol and genistein injections have differential sex-dependent mechanisms of action on murine intestinal Cl(-) secretion.


Asunto(s)
Adenilil Ciclasas/metabolismo , Cloruros/metabolismo , Receptor alfa de Estrógeno/metabolismo , Genisteína/farmacología , Yeyuno/metabolismo , Fitoestrógenos/farmacología , Actinas/metabolismo , Inhibidores de Adenilato Ciclasa , Animales , Colforsina/farmacología , Activadores de Enzimas/farmacología , Estradiol/análogos & derivados , Estradiol/farmacología , Antagonistas de Estrógenos/farmacología , Receptor alfa de Estrógeno/agonistas , Receptor alfa de Estrógeno/antagonistas & inhibidores , Receptor beta de Estrógeno/metabolismo , Femenino , Fulvestrant , Iminas/farmacología , Secreciones Intestinales/efectos de los fármacos , Yeyuno/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos C57BL , Orquiectomía , Piperidinas/farmacología , Pirazoles/farmacología , Caracteres Sexuales , Transducción de Señal
20.
J Pharm Pharmacol ; 64(5): 644-53, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22471360

RESUMEN

OBJECTIVES: Zinc is a useful addition to oral rehydration therapy for acute diarrhoea. We have assessed the mechanism of its epithelial antisecretory action when intestinal epithelial tight junctions were pharmacologically opened. METHODS: Rat isolated ileal and colonic mucosae were mounted in Ussing chambers and exposed to ZnSO(4) (Zn(2+) ) in the presence of secretagogues and inhibition of short circuit current (I(sc) ) was measured. KEY FINDINGS: Pre-incubation with basolateral but not apical Zn(2+) reduced I(sc) stimulated by forskolin, carbachol and A23187. In the presence of the tight junction-opener, cytochalasin D, antisecretory effects of apically-applied Zn(2+) were enabled in colon and ileum. The apparent permeability coefficient (P(app) ) of Zn(2+) was increased 1.4- and 2.4-fold across rat ileum and colon, respectively, by cytochalasin D. Basolateral addition of Zn(2+) also reduced the I(sc) stimulated by nystatin in rat colon, confirming K channel inhibition. In comparison with other inhibitors, Zn(2+) was a relatively weak blocker of basolateral K(ATP) and K (Ca2+) channels. Exposure of ileum and colon to Zn(2+) for 60 min had minimal effects on epithelial histology. CONCLUSIONS: Antisecretory effects of Zn(2+) on intestinal epithelia arose in part through nonselective blockade of basolateral K channels, which was enabled when tight junctions were open.


Asunto(s)
Diarrea/tratamiento farmacológico , Mucosa Intestinal/efectos de los fármacos , Secreciones Intestinales/efectos de los fármacos , Iones/metabolismo , Canales de Potasio/efectos de los fármacos , Uniones Estrechas/fisiología , Zinc/farmacología , Animales , Antidiarreicos/farmacología , Antidiarreicos/uso terapéutico , Calcimicina/farmacología , Carbacol/farmacología , Colforsina/farmacología , Colon/efectos de los fármacos , Citocalasina D/farmacología , Diarrea/fisiopatología , Electricidad , Íleon/efectos de los fármacos , Mucosa Intestinal/fisiopatología , Secreciones Intestinales/fisiología , Ionóforos/farmacología , Masculino , Nistatina/farmacología , Permeabilidad , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio/fisiología , Ratas , Ratas Wistar , Uniones Estrechas/efectos de los fármacos , Zinc/uso terapéutico , Sulfato de Zinc/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...